| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| zanubrutinib | tyrosine-protein kinase blk | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase blk | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | cytoplasmic tyrosine-protein kinase bmx | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | cytoplasmic tyrosine-protein kinase bmx | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase btk | small molecule | Successful target | TTD , drugbank , DGIDB | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
9.09 | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase btk | small molecule | Successful target | TTD , drugbank , DGIDB | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
9.09 | approved,investigational | inhibitor |
| zanubrutinib | epidermal growth factor receptor | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | epidermal growth factor receptor | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | receptor tyrosine-protein kinase erbb-2 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | receptor tyrosine-protein kinase erbb-2 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | receptor tyrosine-protein kinase erbb-4 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | receptor tyrosine-protein kinase erbb-4 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase fgr | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase fgr | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase frk | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase frk | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase itk/tsk | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase itk/tsk | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase jak2 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase jak2 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase jak3 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase jak3 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase lck | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase lck | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | protein-tyrosine kinase 6 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | protein-tyrosine kinase 6 | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase tec | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase tec | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase txk | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| zanubrutinib | tyrosine-protein kinase txk | small molecule | NA | drugbank | Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Waldenstrom Macroglobulinemia[MeSHID:D008258] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Chronic Lymphocytic Leukemia[MeSHID:D015451] B-Cell Lymphomas[MeSHID:D016393] |
NA | approved,investigational | inhibitor |
| click here to return to the previous page | ||||||||